Country: United Kingdom
Language: English
Source: VMD (Veterinary Medicines Directorate)
Boric Acid, Calcium, Glucose, Magnesium
Norbrook Laboratories Limited
amendedS
Boric Acid, Calcium, Glucose, Magnesium
Expired
Revised: June 2010 ATCVet code amended Page 1 of 4 SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Downlands Calcium Borogluconate 20% w/v PMD Solution for Injection 2. QUALITATIVE AND QUANTITATIVE COMPOSITION ACTIVE SUBSTANCE: Contains Calcium Gluconate 16.6% w/v, Magnesium Hypophosphite Hexahydrate 5.0% w/v, and Glucose Monohydrate 22.0% w/v EACH 400 ML CONTAINS: 5.92 g calcium (provided by calcium gluconate and calcium borogluconate) and 1.84 g magnesium (provided by magnesium hypophosphite hexahydrate) 80 g glucose provided by glucose monohydrate. Also contains 3.40% w/v boric acid. EXCIPIENTS: Chlorocresol 0.1% w/v For a full list of excipients, see section 6.1 3. PHARMACEUTICAL FORM Solution for injection A clear pale yellow solution 4. CLINICAL PARTICULARS 4.1 TARGET SPECIES Sheep 4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES For the treatment of hypocalcaemia complicated by deficiency of magnesium with accompanying hypoglycaemia. In the treatment of pregnancy toxaemia and other metabolic imbalances in periparturient sheep 4.3 CONTRAINDICATIONS Not to be administered by intravenous or intramuscular routes 4.4 SPECIAL WARNINGS FOR EACH TARGET SPECIES No special warning. Revised: June 2010 ATCVet code amended Page 2 of 4 4.5 SPECIAL PRECAUTIONS FOR USE i. Special precautions for use in animals The solution should be warmed to body temperature before administration. ii. Special precautions to be taken by the person administering the veterinary medicinal product to animals Care should be taken to avoid accidental self-injection. If accidental self-injection occurs, seek medical advice. Wash hands after use. 4.6 ADVERSE REACTIONS (FREQUENCY AND SERIOUSNESS) None 4.7 USE DURING PREGNANCY, LACTATION OR LAY Can be safely administered to pregnant and lactating animals 4.8 INTERACTION WITH OTHER MEDICINAL PRODUCTS AND OTHER FORMS OF INTERACTION None known 4.9 AMOUNTS TO BE ADMINISTERED AND ADMINISTRATION ROUTE The solution should be warmed to body temperature before administra Read the complete document